Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a Phase II, randomized, placebo-controlled, dose-finding trial
Genovese MC, Kinnman N, de La Bourdonnaye G et al.
Arthritis Rheum 2011;63:1793–803.
This article reported a Phase II study of atacicept in the patients with rheumatoid arthritis who had failed tumor necrosis factor antagonist therapy. The efficacy, safety, and biological activity of three doses of atacicept were described.
» Read an expert review of this paper